Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LY4214835

Phase 1Small molecule

LY4214835 is one of 20 small molecule programs targeting Neoplasms. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

19

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeoplasmsRecruiting

NeoplasmsPhase 1

Recruiting

Competition

Competitive Landscape

29 competitors in Neoplasms

#DrugCompanyPhaseTrials

Alimta

Fludara

Camptosar

Verzenio

Gemzar

Johnson & Johnson

Cyramza

Cytoxan

BBaxter Healthcare Corporation

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Navelbine

PPierre Fabre Medicament

Tasigna

AAzurity Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Neoplasms

NCT07258836

Clinical

Trials by Indication[1]

Neoplasms1 trial

A Phase 1, Open-Label Study to Evaluate the Safety, Biodistribution, Imaging Characteristics, and Radiation Dosimetry of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT07258836·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LY4214835. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY4214835 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY4214835. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eli Lilly

Related News